- Home
- / Mainz BioMed
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Mainz BioMed financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-29
Market Capitalization
$6.9 M
2024-10-29
Revenue
$893 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|
| Revenue | 281.0K | 493.0K | 577.0K | 529.0K | 895.0K | 893.0K |
| Cost of goods sold | 246.0K | 285.0K | 291.0K | 347.0K | 376.0K | 329.0K |
| Gross profit | 35.0K | 208.0K | 286.0K | 593.0K | 519.0K | 564.0K |
| Gross profit margin, % | 12.5% | 42.2% | 49.6% | 112.1% | 58.0% | 63.2% |
| Operating expense total | 902.0K | 822.0K | 9.9M | 26.5M | 26.3M | 18.2M |
| Depreciation and amortization | 54.0K | 60.0K | 69.0K | 261.0K | 876.0K | 1.1M |
| EBITDA | (867.0K) | (614.0K) | (9.7M) | (25.9M) | (25.7M) | (17.6M) |
| EBITDA margin, % | -308.5% | -124.5% | -1673.7% | -4899.1% | -2873.7% | -1975.4% |
| EBIT | (921.0K) | (674.0K) | (9.7M) | (26.2M) | (25.5M) | (20.6M) |
| EBIT margin, % | -327.8% | -136.7% | -1685.6% | -4948.4% | -2847.6% | -2304.0% |
| Interest expense | 202.0K | 268.0K | 2.4M | 210.0K | 810.0K | 1.1M |
| Pre tax profit | (957.0K) | (587.0K) | (11.7M) | (26.4M) | (26.3M) | (21.7M) |
| Net Income | (957.0K) | (587.0K) | (11.7M) | (26.4M) | (26.3M) | (21.7M) |